Oral HRS-7535 Lowered A1c in Trial
Nonpeptide oral agent requires no fasting administration.
By
Kathryn Wighton
June 5, 2026
Clinical Scorecard: Oral HRS-7535 Lowered A1c in Trial
At a Glance
Category Detail
Condition Type 2 Diabetes Key Mechanisms Nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) Target Population Patients aged 18 to 75 years with inadequately controlled type 2 diabetes on metformin Care Setting Phase 2 randomized controlled trial across 44 centers in China
Key Highlights
HRS-7535 reduced hemoglobin A1c levels compared to placebo after 16 weeks. Patients achieved hemoglobin A1c levels below 7.0% ranged from 49% to 63% in HRS-7535 groups versus 15% in placebo. Gastrointestinal adverse events were the most common treatment-related events, predominantly mild or moderate. Guideline-Based Recommendations
Diagnosis
Eligible patients had hemoglobin A1c levels of 7.5% to 11.0%. Management
HRS-7535 was administered once daily at doses of 15 mg, 30 mg, 60 mg, or 90 mg. Monitoring & Follow-up
Monitor hemoglobin A1c levels and gastrointestinal adverse events. Risks
Gastrointestinal adverse events occurred in 72% to 85% of patients receiving HRS-7535. Patient & Prescribing Data
194 patients aged 18 to 75 years with type 2 diabetes inadequately controlled with metformin.
Rescue antihyperglycemic therapy was required in 3% to 8% of patients receiving HRS-7535 compared to 31% in placebo.
Clinical Best Practices
Consider the patient's body mass index and demographics when interpreting trial results. Titrate doses carefully to manage gastrointestinal tolerability. Related Resources & Content
